Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Feb 4, 2014 at 4:29 PM EST

Despite Size, Gilead Keeps Growing and Growing

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers…

Jon C. Ogg | Feb 4, 2014 at 11:30 AM EST

IBS Drug Success: The Fast and the Furiex

Usually when you see stocks double, it is based on a buyout or a major partnership development. That is not…

Jon C. Ogg | Feb 1, 2014 at 8:05 AM EST

CytRx Flushed Its Shareholders, Even If It Needed the Capital

CytRx Corporation (NASDAQ: CYTR) saw its shares get punished on Friday for a secondary offering. Frankly, the pricing of the…

Jon C. Ogg | Jan 31, 2014 at 10:35 AM EST

Three Biotech IPOs Hit on Friday, After Major IPO on Thursday

Six IPOs hit the market Friday , and three of them were biotechs. What stands out is that these emerging…

cgblaine22 | Jan 29, 2014 at 12:10 PM EST

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 28, 2014 at 4:13 PM EST

Amgen Nails Earnings, Guidance a Different Story

ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings…

Jon C. Ogg | Jan 28, 2014 at 7:30 AM EST

Pfizer Delivers on Earnings, Sets 2014 Guidance

Pfizer has managed to handily beat consensus fourth-quarter earnings expectations, at least on the surface. It also offered guidance for…

Jon C. Ogg | Jan 27, 2014 at 11:05 AM EST

Analyst Team Sees Strong Biotech Buyout Market in 2014

Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report…

Jon C. Ogg | Jan 27, 2014 at 8:50 AM EST

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Once again, the analysts at Piper Jaffray are conducting extensive management meetings with the companies they cover. Here are the…

Jon C. Ogg | Jan 23, 2014 at 10:25 AM EST

Ariad Joins Rumor Mill: Hope May Trump Reality

Ariad Pharmaceuticals could be joining the ranks of the next big biotech acquisitions. The company fits the bill of many…

Jon C. Ogg | Jan 22, 2014 at 12:43 PM EST

Has ThermoGenesis Peaked?

ThinkstockThermoGenesis Corp. (NASDAQ: KOOL) is seeing a day-two run in its stock, but investors might want to pay close attention…

Trey Thoelcke | Jan 22, 2014 at 9:05 AM EST

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we…

Trey Thoelcke | Jan 22, 2014 at 7:30 AM EST

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.…

Jon C. Ogg | Jan 16, 2014 at 8:15 AM EST

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

The analysts at Piper Jaffray have returned from meeting with some of the top biotechs the cover, and they have…

1 … 294 295 296 297 298 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Despite Size, Gilead Keeps Growing and Growing

IBS Drug Success: The Fast and the Furiex

CytRx Flushed Its Shareholders, Even If It Needed the Capital

Three Biotech IPOs Hit on Friday, After Major IPO on Thursday

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Amgen Nails Earnings, Guidance a Different Story

Pfizer Delivers on Earnings, Sets 2014 Guidance

Analyst Team Sees Strong Biotech Buyout Market in 2014

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Ariad Joins Rumor Mill: Hope May Trump Reality

Has ThermoGenesis Peaked?

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

The Roth Conversion Strategy Affluent Couples Over 60 Are Using to Drain a $1.4 Million 401(k) Before RMDs Begin

D-Wave Rewarded Patient Investors With 135% Gains but Recent Buyers Face a Brutal Reality

CPI Just Spelled Bad News for Social Security COLA — Even Though it May Not Seem That Way

The Roth Conversion Strategy Affluent Couples Over 60 Are Using to Drain a $1.4 Million 401(k) Before RMDs Begin

Fidelity's 2026 Retirement Study Says 7-in-10 Americans Would Skip Traditional Retirement for Gig Work, a Business, or a New Career

Can iQIYI Stock Double in 2027? The AI Turnaround Case

The Roth Conversion Strategy Affluent Couples Over 60 Are Using to Drain a $1.4 Million 401(k) Before RMDs Begin

Health and Healthcare Articles

All Health and Healthcare Articles

Despite Size, Gilead Keeps Growing and Growing

IBS Drug Success: The Fast and the Furiex

CytRx Flushed Its Shareholders, Even If It Needed the Capital

Three Biotech IPOs Hit on Friday, After Major IPO on Thursday

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Amgen Nails Earnings, Guidance a Different Story

Pfizer Delivers on Earnings, Sets 2014 Guidance

Analyst Team Sees Strong Biotech Buyout Market in 2014

Piper Jaffray’s Seven Biotech Stocks to Buy With Huge Potential Upside

Ariad Joins Rumor Mill: Hope May Trump Reality

Has ThermoGenesis Peaked?

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

The Roth Conversion Strategy Affluent Couples Over 60 Are Using to Drain a $1.4 Million 401(k) Before RMDs Begin

D-Wave Rewarded Patient Investors With 135% Gains but Recent Buyers Face a Brutal Reality

CPI Just Spelled Bad News for Social Security COLA — Even Though it May Not Seem That Way

Featured Reads

The Roth Conversion Strategy Affluent Couples Over 60 Are Using to Drain a $1.4 Million 401(k) Before RMDs Begin

Fidelity's 2026 Retirement Study Says 7-in-10 Americans Would Skip Traditional Retirement for Gig Work, a Business, or a New Career